A Review of Current Evidence with Continuous Glucose Monitoring in Patients with Diabetes
Open Access
- 1 July 2008
- journal article
- review article
- Published by SAGE Publications in Journal of Diabetes Science and Technology
- Vol. 2 (4) , 718-727
Abstract
Devices that measure glucose on a near-continuous basis may provide a better insight into glycemic profiles, allowing patients with diabetes to make therapeutic adjustments to improve metabolic control, thereby reducing the risk of diabetic complications. Motivated and technologically adept patients with brittle diabetes, hypoglycemia unawareness, diabetic pregnancy, or who use pumps might benefit. Current evidence of continuous glucose monitoring (CGM) on health outcome in patients with diabetes is critically reviewed. No data are available on chronic complications or mortality. Therefore, surrogate endpoints need to be investigated, particularly HbA1c, number of hypo- and hyperglycemic episodes, time within normal, high, or low glucose concentrations, glycemic variability, and quality of life. Randomized controlled trials (RCTs) using CGM in a retrospective way did not show metabolic improvement. In contrast, most RCTs applying real-time CGM showed a decrease in HbA1c, reduced glycemic variability, and a diminished number and length of hypo- and hyperglycemic events. Using accurate, real-time CGM devices improves quality of life by reducing the fear of unexpected hypoglycemic events. These beneficial effects were observed despite the fact that in most studies no clear treatment algorithm based on CGM results was provided to the patients. However, most trials were too short in duration, with a variable use of CGM, and were performed in small study samples. In conclusion, real-time CGM systems can improve metabolic control, reduce hypoglycemic episodes, and improve quality of life. Whether this holds true for longer time periods and in the majority of patients remains to be proven. In the long term, CGM might help to reduce chronic diabetes complications and perhaps also mortality, thereby reducing health care costs.Keywords
This publication has 56 references indexed in Scilit:
- Response to Comment on: Chang et al. (2007) Association Study of the Genetic Polymorphisms of the Transcription Factor 7-like 2 (TCF7L2) Gene and Type 2 Diabetes in the Chinese Population: Diabetes 56:2631–2637Diabetes, 2007
- Continuous Glucose Monitoring in Children with Type 1 DiabetesThe Journal of Pediatrics, 2007
- The role of continuous glucose monitoring in clinical decision‐making in diabetes in pregnancyAustralian and New Zealand Journal of Obstetrics and Gynaecology, 2007
- Nocturnal hypoglycaemia in Type 1 diabetic patients, assessed with continuous glucose monitoring: frequency, duration and associationsDiabetic Medicine, 2007
- Continuous subcutaneous glucose monitoring in children with type 1 diabetes mellitus: a single-blind, randomized, controlled trialPediatric Diabetes, 2006
- Results of a Randomised Controlled Cross-Over Trial on the Effect of Continuous Subcutaneous Glucose Monitoring (CGMS) on Glycaemic Control in Children and Adolescents with Type 1 DiabetesExperimental and Clinical Endocrinology & Diabetes, 2006
- Use of the Continuous Glucose Monitoring System to Guide Therapy in Patients With Insulin-Treated Diabetes: A Randomized Controlled TrialMayo Clinic Proceedings, 2004
- Improved metabolic control in diabetic adolescents using the continuous glucose monitoring system (CGMS)Diabetes & Metabolism, 2003
- Continuous Subcutaneous Glucose Monitoring in Children With Type 1 DiabetesPediatrics, 2001
- Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)The Lancet, 1998